BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 19647222)

  • 1. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling.
    Gewinner C; Wang ZC; Richardson A; Teruya-Feldstein J; Etemadmoghadam D; Bowtell D; Barretina J; Lin WM; Rameh L; Salmena L; Pandolfi PP; Cantley LC
    Cancer Cell; 2009 Aug; 16(2):115-25. PubMed ID: 19647222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers.
    Fedele CG; Ooms LM; Ho M; Vieusseux J; O'Toole SA; Millar EK; Lopez-Knowles E; Sriratana A; Gurung R; Baglietto L; Giles GG; Bailey CG; Rasko JE; Shields BJ; Price JT; Majerus PW; Sutherland RL; Tiganis T; McLean CA; Mitchell CA
    Proc Natl Acad Sci U S A; 2010 Dec; 107(51):22231-6. PubMed ID: 21127264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC.
    Reed DE; Shokat KM
    Mol Cancer Res; 2017 Jun; 15(6):765-775. PubMed ID: 28196852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The INPP4B paradox: Like PTEN, but different.
    Hamila SA; Ooms LM; Rodgers SJ; Mitchell CA
    Adv Biol Regul; 2021 Dec; 82():100817. PubMed ID: 34216856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. INPP4B: the new kid on the PI3K block.
    Agoulnik IU; Hodgson MC; Bowden WA; Ittmann MM
    Oncotarget; 2011 Apr; 2(4):321-8. PubMed ID: 21487159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deletion of inositol polyphosphate 4-phosphatase type-II B affects spermatogenesis in mice.
    Ceyhan Y; Zhang M; Guo J; Sandoval CG; Vacher J; Kaftanovskaya EM; Agoulnik AI; Agoulnik IU
    PLoS One; 2020; 15(5):e0233163. PubMed ID: 32413098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes.
    Li Chew C; Lunardi A; Gulluni F; Ruan DT; Chen M; Salmena L; Nishino M; Papa A; Ng C; Fung J; Clohessy JG; Sasaki J; Sasaki T; Bronson RT; Hirsch E; Pandolfi PP
    Cancer Discov; 2015 Jul; 5(7):740-51. PubMed ID: 25883022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
    Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
    Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A tumor suppressor function for the lipid phosphatase INPP4B in melanocytic neoplasms.
    Perez-Lorenzo R; Gill KZ; Shen CH; Zhao FX; Zheng B; Schulze HJ; Silvers DN; Brunner G; Horst BA
    J Invest Dermatol; 2014 May; 134(5):1359-1368. PubMed ID: 24288008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor β regulates AKT activity through up-regulation of INPP4B and inhibits migration of prostate cancer cell line PC-3.
    Chaurasiya S; Wu W; Strom AM; Warner M; Gustafsson JÅ
    Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26347-26355. PubMed ID: 33020300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of the tumor suppressor INPP4B protein and lipid phosphatase activities.
    Lopez SM; Hodgson MC; Packianathan C; Bingol-Ozakpinar O; Uras F; Rosen BP; Agoulnik IU
    Biochem Biophys Res Commun; 2013 Oct; 440(2):277-82. PubMed ID: 24070612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTEN, but not SHIP2, suppresses insulin signaling through the phosphatidylinositol 3-kinase/Akt pathway in 3T3-L1 adipocytes.
    Tang X; Powelka AM; Soriano NA; Czech MP; Guilherme A
    J Biol Chem; 2005 Jun; 280(23):22523-9. PubMed ID: 15824124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer.
    Hodgson MC; Shao LJ; Frolov A; Li R; Peterson LE; Ayala G; Ittmann MM; Weigel NL; Agoulnik IU
    Cancer Res; 2011 Jan; 71(2):572-82. PubMed ID: 21224358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological and clinical significance of loss of heterozygosity at the INPP4B gene locus in Japanese breast cancer.
    Tokunaga E; Yamashita N; Kitao H; Tanaka K; Taketani K; Inoue Y; Saeki H; Oki E; Oda Y; Maehara Y
    Breast; 2016 Feb; 25():62-8. PubMed ID: 26577950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma.
    Ye Y; Jin L; Wilmott JS; Hu WL; Yosufi B; Thorne RF; Liu T; Rizos H; Yan XG; Dong L; Tay KH; Tseng HY; Guo ST; de Bock CE; Jiang CC; Wang CY; Wu M; Zhang LJ; Hersey P; Scolyer RA; Zhang XD
    Nat Commun; 2013; 4():1508. PubMed ID: 23443536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases.
    Rodgers SJ; Ferguson DT; Mitchell CA; Ooms LM
    Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 28082369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. INPP4B overexpression suppresses migration, invasion and angiogenesis of human prostate cancer cells.
    Chen H; Li H; Chen Q
    Clin Exp Pharmacol Physiol; 2017 Jun; 44(6):700-708. PubMed ID: 28261855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death.
    Weng LP; Smith WM; Dahia PL; Ziebold U; Gil E; Lees JA; Eng C
    Cancer Res; 1999 Nov; 59(22):5808-14. PubMed ID: 10582703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. INPP4B restrains cell proliferation and metastasis via regulation of the PI3K/AKT/SGK pathway.
    Chen Y; Sun Z; Qi M; Wang X; Zhang W; Chen C; Liu J; Zhao W
    J Cell Mol Med; 2018 May; 22(5):2935-2943. PubMed ID: 29516642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment.
    Ip LR; Poulogiannis G; Viciano FC; Sasaki J; Kofuji S; Spanswick VJ; Hochhauser D; Hartley JA; Sasaki T; Gewinner CA
    Oncotarget; 2015 Apr; 6(12):10548-62. PubMed ID: 25868852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.